Linked Life Data

1522080

Source:http://linkedlifedata.com/resource/pubmed/id/1522080

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1992-10-14
pubmed:abstractText
Major depressive disorder is a major health concern. It adversely affects the patient, the family, and society. While the consequences can be devastating and life-threatening, this condition has an excellent prognosis when properly identified and treated. Somatic therapy plays a pivotal role in inducing and maintaining a remission and preventing recurrent attacks. There are now five major classes of antidepressants which differ in terms of their clinical spectra of antidepressant activity, their safety and tolerability, their likelihood of pharmacodynamic and pharmacokinetic interactions with concomitantly prescribed drugs, ease of administration, and physician confidence, which is in large measure a reflection of the extent and quality of their human exposure database. The proper selection and management of antidepressant pharmacotherapy is based on an understanding of these differences.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0160-6689
pubmed:author
pubmed:issnType
Print
pubmed:volume
53 Suppl
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
5-18
pubmed:dateRevised
2005-11-16
pubmed:meshHeading
pubmed:year
1992
pubmed:articleTitle
Somatic therapy for major depressive disorder: selection of an antidepressant.
pubmed:affiliation
Department of Psychiatry, University of Kansas School of Medicine, Wichita.
pubmed:publicationType
Journal Article, Review